195 related articles for article (PubMed ID: 38173044)
1. Exploring the prognostic potential of m6A methylation regulators in low-grade glioma: implications for tumor microenvironment modulation.
Wu H; Chen S; Hu Z; Ge R; Ma L; You C; Huang Y
Eur J Med Res; 2024 Jan; 29(1):19. PubMed ID: 38173044
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive characterization of tumor microenvironment and m6A RNA methylation regulators and its effects on PD-L1 and immune infiltrates in cervical cancer.
Ji H; Zhang JA; Liu H; Li K; Wang ZW; Zhu X
Front Immunol; 2022; 13():976107. PubMed ID: 36091006
[TBL] [Abstract][Full Text] [Related]
4. Exploring the role of m6A methylation regulators in glioblastoma multiforme and their impact on the tumor immune microenvironment.
Deng X; Sun X; Hu Z; Wu Y; Zhou C; Sun J; Gao X; Huang Y
FASEB J; 2023 Sep; 37(9):e23155. PubMed ID: 37606566
[TBL] [Abstract][Full Text] [Related]
5. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
Front Genet; 2022; 13():872186. PubMed ID: 35937991
[No Abstract] [Full Text] [Related]
6. Characterization of the Clinical Significance of PD-1/PD-Ls Expression and Methylation in Patients With Low-Grade Glioma.
Mei J; Cai Y; Xu R; Yang X; Zhou W; Wang H; Liu C
Technol Cancer Res Treat; 2021; 20():15330338211011970. PubMed ID: 33955303
[TBL] [Abstract][Full Text] [Related]
7. M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.
Liu X; Ma C; Liu H; Sun Z; Luo J
J Cancer Res Clin Oncol; 2022 Oct; 148(10):2803-2814. PubMed ID: 35596010
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value and immune landscaps of m6A/m5C-related lncRNAs signature in the low grade glioma.
Li R; Chen H; Li C; Qi Y; Zhao K; Wang J; You C; Huang H
BMC Bioinformatics; 2023 Jul; 24(1):274. PubMed ID: 37403043
[TBL] [Abstract][Full Text] [Related]
9. N6-methyladenosine with immune infiltration and PD-L1 in hepatocellular carcinoma: novel perspective to personalized diagnosis and treatment.
Shi Y; Wang Y; Zhang W; Niu K; Mao X; Feng K; Zhang Y
Front Endocrinol (Lausanne); 2023; 14():1153802. PubMed ID: 37469973
[TBL] [Abstract][Full Text] [Related]
10. Integrating m6A Regulators-Mediated Methylation Modification Models and Tumor Immune Microenvironment Characterization in Caucasian and Chinese Low-Grade Gliomas.
Liu W; Li C; Wu Y; Xu W; Chen S; Zhang H; Huang H; Zhao S; Wang J
Front Cell Dev Biol; 2021; 9():725764. PubMed ID: 34900988
[No Abstract] [Full Text] [Related]
11. N
Li C; Zhu M; Gao C; Lu F; Chen H; Liu J; Zhong W
Front Biosci (Landmark Ed); 2024 Jan; 29(1):33. PubMed ID: 38287827
[TBL] [Abstract][Full Text] [Related]
12. Expression profiles of m6A RNA methylation regulators, PD-L1 and immune infiltrates in gastric cancer.
Xu Z; Chen Q; Shu L; Zhang C; Liu W; Wang P
Front Oncol; 2022; 12():970367. PubMed ID: 36003776
[TBL] [Abstract][Full Text] [Related]
13. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
14. m6A regulator-mediated methylation modification patterns and characteristics of immunity and stemness in low-grade glioma.
Du J; Ji H; Ma S; Jin J; Mi S; Hou K; Dong J; Wang F; Zhang C; Li Y; Hu S
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33594424
[TBL] [Abstract][Full Text] [Related]
15. m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Acute Myeloid Leukemia.
Du A; Wu X; Gao Y; Jiang B; Wang J; Zhang P; Zhao Q
Front Immunol; 2021; 12():789914. PubMed ID: 34887874
[TBL] [Abstract][Full Text] [Related]
16. Identification of Critical m
Zheng J; Wang X; Qiu Y; Wang M; Yu H; Zhou Z; Wu Z; Jiang X
Biomed Res Int; 2021; 2021():9959212. PubMed ID: 34212046
[TBL] [Abstract][Full Text] [Related]
17. Integrated analysis of inflammatory response subtype-related signature to predict clinical outcomes, immune status and drug targets in lower-grade glioma.
Cao Y; Zhu H; Chen Q; Huang H; Xie D; Li X; Jiang X; Ren C; Peng J
Front Pharmacol; 2022; 13():914667. PubMed ID: 36091778
[No Abstract] [Full Text] [Related]
18. Identification of Implications of Angiogenesis and m6A Modification on Immunosuppression and Therapeutic Sensitivity in Low-Grade Glioma by Network Computational Analysis of Subtypes and Signatures.
Li B; Wang F; Wang N; Hou K; Du J
Front Immunol; 2022; 13():871564. PubMed ID: 35572524
[TBL] [Abstract][Full Text] [Related]
19. Correlation of immune phenotype with IDH mutation in diffuse glioma.
Berghoff AS; Kiesel B; Widhalm G; Wilhelm D; Rajky O; Kurscheid S; Kresl P; Wöhrer A; Marosi C; Hegi ME; Preusser M
Neuro Oncol; 2017 Oct; 19(11):1460-1468. PubMed ID: 28531337
[TBL] [Abstract][Full Text] [Related]
20. Establishment and Validation of a 5 m6A RNA Methylation Regulatory Gene Prognostic Model in Low-Grade Glioma.
Bai Z; Wang X; Zhang Z
Front Genet; 2022; 13():655169. PubMed ID: 35281815
[No Abstract] [Full Text] [Related]
[Next] [New Search]
